Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Observational Study to Explore the Efficacy of Eribulin as 1st-line or 2nd-line Chemotherapy in Patients With HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer

NCT02551263 is registered in ClinicalTrials.gov with Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan as lead sponsor.

NCT NCT02551263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02551263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Observational Study to Explore the Efficacy of Eribulin as 1st-line or 2nd-line Chemotherapy in Patients With HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer
Lead sponsor
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase
Observational
Overall status
Completed
Start date
July 22, 2015
Completion date
July 31, 2020
Enrollment
201 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer